Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain

Neuropsychopharmacology

Volumn 40, Issue 3, 2015, Pages 650-657

  Fowler, Joanna S ^a   Logan, Jean ^b   Volkow, Nora D ^c,d   Shumay, Elena ^d   McCall Perez, Fred ^e   Jayne, Millard ^d   Wang, Gene Jack ^d   Alexoff, David L ^a   Apelskog Torres, Karen ^d   Hubbard, Barbara ^a   Carter, Pauline ^a   King, Payton ^a   Fahn, Stanley ^f   Gilmor, Michelle ^g   Telang, Frank ^d   Shea, Colleen ^a   Xu, Youwen ^a   Muench, Lisa ^d  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^e Targeted Medical Pharma Inc   (United States)

^f NewYork Presbyterian Hospital   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CLORGYLINE C 11; COCAINE C 1; DOPAMINE TRANSPORTER; SELEGILINE; TRACER; UNCLASSIFIED DRUG; AMINE OXIDASE (FLAVIN CONTAINING); CARBON; CLORGYLINE; COCAINE; MONOAMINE OXIDASE A, HUMAN; MONOAMINE OXIDASE INHIBITOR;

ADULT; ARTICLE; BRAIN; CHRONOTHERAPY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MEGADOSE; DRUG TARGETING; DRUG UPTAKE; FIRST PASS EFFECT; HUMAN; MALE; MEDICATION COMPLIANCE; NORMAL HUMAN; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SINGLE DRUG DOSE; TRANSDERMAL PATCH; ADOLESCENT; CLINICAL TRIAL; CUTANEOUS DRUG ADMINISTRATION; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; FUNCTIONAL NEUROIMAGING; METABOLISM; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BRAIN; CARBON RADIOISOTOPES; CLORGYLINE; COCAINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FUNCTIONAL NEUROIMAGING; HUMANS; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; POSITRON-EMISSION TOMOGRAPHY; SELEGILINE; YOUNG ADULT;

EID: 84922105814     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.214     Document Type: Article

References (45)

1. Alexoff DL, Shea C, Fowler JS, King P, Gatley SJ, Schlyer DJ et al (1995). Plasma input function determination for PET using a commercial laboratory robot. Nucl Med Biol 22: 893-904.
2. Amsterdam JD (2003). A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 64: 208-214.
3. Alia-Klein N, Goldstein RZ, Kriplani A, Logan J, Tomasi D, Williams B et al (2008). Brain monoamine oxidase A activity predicts trait aggression. J Neurosci 28: 5099-5104.
4. Azzaro AJ, Vandenberg CM, Blob LF, Kemper EM, Sharoky M, Oren DA et al (2006). Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J Clin Pharmacol 46: 933-944.
5. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C (2007). Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol 47: 1256-1267.
6. Bodkin JA, Amsterdam JD (2002). Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 159: 1869-1875.
7. Clarke A, Brewer F, Johnson ES, Mallard N, Hartig F, Taylor S et al (2003a). A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 110: 1241-1255.
8. Clarke A, Johnson ES, Mallard N, Corn TH, Johnston A, Boyce M et al (2003b). A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm 110: 1257-1271.
9. Dorfman HM, Meyer-Lindenberg A, Buckholtz JW (2014). Neurobiological mechanisms for impulsive-aggression: the role of MAOA. Curr Top Behav Neurosci 17: 297-313.
10. Engberg G, Elebring T, Nissbrandt H (1991). Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J Pharmacol Exp Ther 259: 841-847.
11. Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS (2006). Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 67: 1354-1361.
12. Finberg JPM (2014). Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulations of CNS monoamine neurotransmitter release. Pharmacol Ther 143: 133-152.
13. Finberg JP, Gillman K (2011). Selective inhibitors of monoamine oxidase type B and the 'cheese effect'. Int Rev Neurobiol 100: 169-190.
14. Fowler JS, Azzaro AJ, Fielding RM, Zhu W, Pohusta AK et al (2010). Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology 35: 623-631.
15. Fowler JS, Volkow ND, Logan J, Franceschi D, Wang GJ, MacGregor R et al (2001). Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. Life Sci 68: 2759-2768.
16. Fowler JS, Volkow ND, Wang G-J, Pappas N, Logan J, MacGregor RR et al (1996). Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 93: 14065-14069.
17. Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, Macgregor RR et al (1989). Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 4: 371-377.
18. Fowler JS, Alia-Klein N, Kriplani A, Logan J, Williams B, Zhu W et al (2007). Evidence that brain MAO A activity does not correspond to MAO A genotype in healthy male subjects. Biol Psychiatry 62: 355-358.
19. Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE et al (1990). Smoking, smoking cessation, and major depression. JAMA 264: 1546-1549.
20. Lamensdorf I, Porat S, Simantov R, Finberg JP (1999). Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Br J Pharmacol 126: 997-1002.
21. Lerman C, Audrain J, Orleans CT, Boyd R, Gold K, Main D et al (1996). Investigation of mechanisms linking depressed mood to nicotine dependence. Addict Behav 21: 9-19.
22. Lipper S, Murphy DL, Slater S, Buchsbaum MS (1979). Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology (Berl) 62: 123-128.
23. Logan J, Dewey SL, Wolf AP, Fowler JS, Brodie JD, Angrist B et al (1991). Effects of endogenous dopamine on measures of [18F]Nmethylspiroperidol binding in the basal ganglia: comparison of simulations and experimental results from PET studies in baboons. Synapse 9: 195-207.
24. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ et al (1990). Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10: 740-747.
25. Löhle M, Storch A (2008). Orally disintegrating selegiline for the treatment of Parkinson's disease. Expert Opin Pharmacother 9: 2881-2891.
26. MacGregor RR, Fowler JS, Wolf AP, Halldin C, Langstrom B (1988). Synthesis of suicide inhibitors of monoamine oxidase: carbon-11 labeled clorgyline, L-deprenyl and D-deprenyl. J Labeled Compounds Radiopharm 25: 1-9.
27. Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T et al (1989). A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 46: 45-50.
28. Mawhinney M, Cole D, Azzaro AJ (2003). Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol 55: 27-34.
29. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A et al (2006). Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63: 1209-1216.
30. Pomerleau OF, Pomerleau CS (1984). Neuroregulators and the reinforcement of smoking: towards a biobehavioral explanation. Neurosci Biobehav Rev 8: 503-513.
31. Prasad A, Glover V, Goodwin BL, Sandler M, Signy M, Smith SE (1988). Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment. Psychopharmacology (Berl) 95: 540-543.
32. Riederer P, Youdim MB (1986). Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem 46: 1359-1365.
33. Robinson JB (1985). Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl. Biochem Pharmacol 34: 4105-4108.
34. Sabol SZ, Hu S, Hamer D (1998). A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genetics 103: 273.
35. Santana L, González-D?áz H, Quezada E, Uriarte E, Yáñez M, Vinã D et al (2008). Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem 51: 6740-6751.
36. Schulz R, Antonin KH, Hoffmann E, Jedrychowski M, Nilsson E, Schick C et al (1989). Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 46: 528-536.
37. Shulman KI, Herrmann N, Walker SE (2013). Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs 27: 789-797.
38. Smith B, Uhl K (2009). Drug delivery in the twenty-first century: a new paradigm. Clin Pharmacol Ther 85: 451-455.
39. Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL (1985). Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology (Berl) 86: 432-437.
40. Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA et al (1994). High-dose selegiline in treatmentresistant older depressive patients. Arch Gen Psychiatry 51: 607-615.
41. Tong J, Meyer JH, Furukawa Y, Boileau I, Chang LJ, Wilson AA et al (2013). Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab 33: 863-871.
42. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F et al (2009). Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301: 1148-1154.
43. Volkow ND, Wang G-J, Fischman MW, Foltin RW, Fowler JS, Abumrad NN et al (1997). Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386: 827-830.
44. Volkow ND, Wang G-J, Fowler JS, Logan J, Franceschi D, Maynard L et al (2002). Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 34: 181-187.
45. Wiener HL, Hashim A, Lajtha A, Sershen H (1989). Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier. Eur J Pharmacol 163: 191-194.